' '
Deutsch | English    

Forschungsdatenbank PMU-SQQUID

Sex-Based Clinical Outcome in Advanced NSCLC Patients Undergoing PD-1/PD-L1 Inhibitor Therapy-A Retrospective Bi-Centric Cohort Study.
Lang, D; Brauner, A; Huemer, F; Rinnerthaler, G; Horner, A; Wass, R; Brehm, E; Kaiser, B; Greil, R; Lamprecht, B;
Cancers (Basel). 2021; 14(1):
Originalarbeiten (Zeitschrift)

PMU-Autor/inn/en

Greil Richard
Huemer Florian
Rinnerthaler Gabriel
Wass Romana

Abstract


Men with non-small cell lung cancer (NSCLC) have a more favorable response to immune-checkpoint inhibitor (ICI) monotherapy, while women especially benefit from ICI-chemotherapy (CHT) combinations. To elucidate such sex differences in clinical practice, we retrospectively analyzed two cohorts treated with either ICI monotherapy (


Find related publications in this database (Keywords)

immunotherapy
immune-checkpoint inhibitor
response prediction
men and women
pembrolizumab
nivolumab
atezolizumab
ECOG
CRP
chemo-immunotherapy